Moxetumomab pasudotox
- Generic Name
- Moxetumomab pasudotox
- Brand Names
- Lumoxiti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1020748-57-5
- Unique Ingredient Identifier
- 2NDX4B6N8F
- Background
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a reco...
- Indication
MxP is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies including treatment with a purine nucleoside analog. The use of this drug is not recommended in patients with severe renal impairment (CrCl < 29 ml/min).
...
- Associated Conditions
- Relapsed/Refractory Hairy Cell Leukemia
- Associated Therapies
- -
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT03805932
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
- Conditions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03501615
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 37
- Registration Number
- NCT02227108
- Locations
- 🇬🇧
Research Site, Bristol, United Kingdom
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01891981
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01829711
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.